mRNA JABS ARE A FORM OF GENETIC WARFARE

PLUS MF59 Poison Adjuvant In Anthrax Vaccine & Worldwide Flu Vaccines

MF59 is an oil-in-water emulsion adjuvant developed by Novartis to enhance the immune response to influenza vaccines. It has been incorporated into several influenza vaccines, both seasonal and pandemic, across various age groups. Below is a list of vaccines that contain the MF59 adjuvant:

⸻
Seasonal Influenza Vaccines
1. Fluad® (Trivalent)
• Manufacturer: Originally Novartis; now produced by Seqirus.
• Indication: Approved for individuals aged 65 years and older.
• Approval: First approved in Italy in 1997; licensed in over 30 countries, including the United States since 2015.
2. Fluad® Quadrivalent
• Manufacturer: Seqirus.
• Indication: Approved for individuals aged 65 years and older.
• Approval: Approved in the United States in 2020.
3. Fluad® Pediatric
• Manufacturer: Novartis.
• Indication: Designed for children as young as 6 months.
• Approval: Licensed in Canada.

⸻

Pandemic Influenza Vaccines
1. Aflunov®
• Manufacturer: Novartis.
• Type: Prepandemic H5N1 vaccine.
• Approval: Licensed in Europe.
2. Focetria®
• Manufacturer: Novartis.
• Type: Pandemic H1N1 vaccine.
• Approval: Licensed in Europe and Latin America.
3. Celtura®
• Manufacturer: Novartis.
• Type: Cell culture-based H1N1 vaccine.
• Approval: Licensed in some countries in Europe and Latin America.
4. AUDENZ™
• Manufacturer: Seqirus.
• Type: Adjuvanted, cell-based pandemic influenza A (H5N1) vaccine.
• Approval: Approved by the U.S. FDA in 2020.

⸻

These vaccines utilize the MF59 adjuvant to enhance immunogenicity, particularly beneficial for populations such as the elderly and young children who may have a less robust immune response to standard vaccines. The inclusion of MF59 has been shown to improve the efficacy of influenza vaccines and is a critical component in pandemic preparedness strategies.

If you need more detailed information on any of these vaccines or their availability in specific regions, feel free to ask.